Aims The epidemiology of the five stages of chronic kidney disease (CKD) in systolic heart failure (HF) patients has predominantly been described in hospitalized White patients, with little known ...

Recent research has highlighted the epidemiology of CKD, particularly its prevalence in vulnerable populations, such as agricultural workers and children in endemic regions. Factors contributing ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Not having a formal CKD diagnosis significantly increases ... where the field of epidemiology sparked my fascination. I was eager to explore its real-world implications rather than focusing ...

Background: Approximately 10% of adults in Germany have chronic kidney disease (CKD). The prevalence of CKD among patients being cared for by general practitioners is approximately 30% ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

CKD affects around 37 million adults in the US and is expected to rise in line with diabetes prevalence. The disease is ...

Taking charge of your health is one of the most powerful choices you can make, and prioritising your kidneys plays a vital ...

The study population consisted of 1301 patients. A total of 338 patients (26%) with HF were found to have CKD. Demographic and clinical characteristics according to the presence or absence of CKD ...

Semaglutide was also found to be superior to placebo for the confirmatory secondary endpoints, which included annual rate of change in eGFR (CKD-EPI), time to occurrence of a major adverse CV ...

Background: Approximately 10% of adults in Germany have chronic kidney disease (CKD). The prevalence of CKD among patients being cared for by general practitioners is approximately 30% ...